Phase 2 N=30 Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy
Hyperemesis Gravidarum · Nausea Gravidarum · Vomiting of Pregnancy
Primary: Time to Symptom Control — 72; 87 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=49 Non-invasive Vagal Nerve Stimulation (nVNS) for Symptomatic Exacerbation of Nausea in Patients With Gastroparesis and Related Disorders
Chronic Unexplained Nausea and Vomiting · Gastroparesis
Primary: Average Daily Use of Rescue Medications for Exacerbation of Nausea/Vomiting. — 1.186; 0.551; 0.754; 0.447 medications/day
Phase 2 N=31 Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum
Hyperemesis Gravidarum
Primary: Baseline Adjusted Mean Daily Motherisk-PUQE Total Scores (Pregnancy-unique Quantification of Emesis and Nausea Scale) for Days 5-7 — 6.35; 13.22 units on a scale — p=0.01
Phase 3 N=280 The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy
Nausea and Vomiting of Pregnancy
Primary: Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall…
Phase 2 N=126 Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial
Gastroparesis
Primary: Number of Participants With Improvement in Nausea — 29; 25 participants — p=0.43
Phase 4 N=20 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Ovarian Cancer · Uterine Cancer
Primary: Overall Complete Response Rate — 10; 10 percentage of participants
N/A N=300 Management of Nausea and Vomiting Chemotherapy-induced in Normandy
Cancer · Nausea · Vomiting
Primary: Number of Participants With Acute Nausea and Vomiting — 101 Participants
Phase 3 N=317 Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
Breast Carcinoma
Primary: Average Nausea Defined as the Average [ MAXIMUM ] Nausea Rating Across 15 Assessment Points at Cycle 1 and 16 Assessment Points at Cycle 2 (Comparing Prochlorperazine or…
N/A N=306 Prevention of Intraoperative Nausea and Vomiting During Cesarean Section
Cesarean Delivery
Primary: Intraoperative Nausea and Vomiting — 23; 31; 49 participants
N/A N=200 Accupressure of P6 to Reduce Nausea During Cesarean Section
Pregnancy Related · Cesarean Delivery · Nausea
Primary: Presence of Intraoperative Vomiting — 17; 17 Participants — p=.94
N/A N=108 Defining Adolescent Nausea Through Brain Imaging and Neurostimulation Response
Functional Gastrointestinal Disorders
Primary: Nausea Severity Scale — 2.18; 2.45 units on a scale
Phase 2 N=30 Topical Capsaicin for Cyclical Vomiting
Cyclical Vomiting
Primary: Nausea Visual Analog Scale — 41; 61 mm
Phase 3 N=30 Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
Advanced Cancer
Primary: Mean Nausea Scores — 1; 9 units on a scale
Phase 4 N=180 Acupuncture Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean
Nausea · Vomiting · Satisfaction
Primary: Nausea — 44; 14; 22 Participants — p=< 0.00001
Phase 2 N=64 Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department
Nausea and Vomiting
Primary: Vomiting at 0 to 120 Min. — 1; 4 number of participants exp vomiting
N/A N=115 Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
Nausea · Vomiting
Primary: Number of Participants With Nausea and Vomiting — 24; 29 participants
N/A N=242 Alternative Approaches for Nausea Control
Nausea
Primary: Patient Report Nausea Diary — 3.87; 3.55; 3.52 units on a scale — p=.05
Phase 3 N=216 A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)
Post-Operative Nausea and Vomiting
Primary: Number of Patients With Clinical Adverse Experiences (CAEs) — 125; 32 Participants
N/A N=9 Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Patients With Gastroparesis Who Have Failed Standard Therapy
Primary: Improvement of Overall Symptoms Based on Likert Scale — 2 Participants
N/A N=27,034 Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis
Postoperative Nausea and Vomiting
Primary: Adherence to PONV Guidelines — 666; 5260; 5863 Participants
N/A N=180 Prevention of Postoperative Nausea and Vomiting (PONV) in Surgical Patients
Postoperative Nausea and Vomiting
Primary: Incidence of Postoperative Nausea and Vomiting — 34.4; 29.8; 12.5; 7 percentage of participants — p=>0.76
Phase 4 N=289 The Montefiore Metoclopramide Study
Nausea · Extrapyramidal Symptoms
Primary: Nausea Scale — 0; 0; 0; 0 units on a scale
Phase 3 N=46 Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
Malignant Neoplasm · Nausea · Vomiting
Primary: Change in Nausea Numerical Rating Scale (NRS) Between Day 5 and Day 15 — -2.0; -2.3 score on a scale — p=0.98
N/A N=115 Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
Nausea · Vomiting
Primary: Number of Participants With Postoperative Nausea and Vomiting — 28; 34 participants
Phase 4 N=54 Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis
Postoperative Nausea and Vomiting
Primary: PONV Incidence — 12 participants
Phase 3 N=1,455 An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1 — 76.9; 69.5 percentage of responders — p=0.001
Phase 1 N=10 Phase I Study of Nicotinamide for Early Onset Preeclampsia
Pregnancy Induced Hypertension · Superimposed Preeclampsia · Hypertension
Primary: Number of Participants With Adverse Events — 2; 0 participants
Phase 3 N=405 A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Adverse Events — 169; 174; 86; 90 Participants
Phase 2 N=257 Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)
Postoperative Nausea and Vomiting
Primary: Experienced Post-operative Nausea or Vomiting — 25; 29; 20; 30 participants
Phase 3 N=1,147 Phase IIIb Study of APD421 in Combination as PONV Prophylaxis
PONV
Primary: Number of Participants With Complete Response — 330; 268 Participants — p=<0.001